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M.W. Weiner et al. / Alzheimer’s & Dementia 10 (2014) S226-S235 S227Abstract Both traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) are common problems
resulting frommilitary service, and both have been associated with increased risk of cognitive decline
and dementia resulting fromAlzheimer’s disease (AD) or other causes. This study aims to use imaging
techniques and biomarker analysis to determine whether traumatic brain injury (TBI) and/or PTSD
resulting from combat or other traumas increase the risk for AD and decrease cognitive reserve in Vet-
eran subjects, after accounting for age. Using military and Department of Veterans Affairs records, 65
Vietnam War veterans with a history of moderate or severe TBI with or without PTSD, 65 with
ongoing PTSD without TBI, and 65 control subjects are being enrolled in this study at 19 sites.
The study aims to select subject groups that are comparable in age, gender, ethnicity, and education.
Subjects with mild cognitive impairment (MCI) or dementia are being excluded. However, a new
study just beginning, and similar in size, will study subjects with TBI, subjects with PTSD, and control
subjects withMCI. Baseline measurements of cognition, function, blood, and cerebrospinal fluid bio-
markers;magnetic resonance images (structural, diffusion tensor, and resting state blood-level oxygen
dependent (BOLD) functional magnetic resonance imaging); and amyloid positron emission tomo-
graphic (PET) images with florbetapir are being obtained. One-year follow-up measurements will
be collected for most of the baseline procedures, with the exception of the lumbar puncture, the
PET imaging, and apolipoprotein E genotyping. To date, 19 subjects with TBI only, 46 with PTSD
only, and 15 with TBI and PTSD have been recruited and referred to 13 clinics to undergo the study
protocol. It is expected that cohorts will be fully recruited by October 2014. This study is a first step
toward the design and statistical powering of an AD prevention trial using at-risk veterans as subjects,
and provides the basis for a larger, more comprehensive study of dementia risk factors in veterans.
 2014 Published by Elsevier Inc. on behalf of The Alzheimer’s Association.Keywords: Traumatic brain injury; Posttraumatic stress disorder; Alzheimer’s disease; Veterans; Neuroimaging1. Introduction
Post-traumatic stress disorder (PTSD) and traumatic
brain injury (TBI) are well-documented risk factors for Alz-
heimer’s disease (AD) [1–3]. AD is characterized by brain
pathology consisting of extracellular plaques containing
amyloid-b (Ab), tangles of phosphorylated tau protein
inside neurons, synapse loss, and neuronal loss, leading to
dementia. Imaging studies using magnetic resonance
imaging (MRI) and positron emission tomography (PET),
and analysis of proteins in cerebrospinal fluid (CSF) have
revealed that AD is associated with low concentrations of
CSF Ab and elevated tau or, equivalently, the high uptake
of an Ab [4] imaging agent such as [11C] Pittsburgh com-
pound B, or the more recently developed [18F]-labeled amy-
loid PET ligands, such as florbetapir. Volumetric MRI has
identified reduced volume of the entorhinal cortex, and hip-
pocampus, and cortical thinning of the temporal and parietal
cortices as being characteristic of AD [5].
TBI is defined as traumatically induced physiological
disruption of brain function, as manifested by loss of con-
sciousness, memory impairment, alteration of mental state,
and/or focal neurological deficits. Diffuse injuries include
hypoxia/ischemia, vascular damage, and diffuse macro-/
microstructural axonal injury. Numerous epidemiologic
studies have linked TBI to AD (reviewed in [6–12]). A
history of TBI may be associated with earlier onset of AD
[1,6,7,13–16] and the apolipoprotein E ε4 (APOE ε4) allele
may worsen outcome [13,17–28]. Ab plaques and intra-
axonal Ab deposits were found in approximately one-third
of TBI subjects who died sometime after the TBI insult[29–36]. A biopsy study of TBI survivors confirmed Ab
pathology [37,38], even in young subjects, suggesting that
TBI is causal [31,35]. Repetitive mild TBI is associated
with the development of chronic traumatic encephalopathy
(CTE), a progressive tauopathy, and TAR DNA-binding
protein 43 (TDP-43) proteinopathy that may also result in a
late-life dementia [39]. CTE is distinguished from AD by
the relative lack of Ab-containing neuritic plaques and by at-
rophy of the medial temporal lobe, diencephalon, and
mammillary bodies only in late stages of disease [39], but
the link between the two conditions is not yet clear. One pos-
sibility is that TBI is associated with CTE, which manifest as
a form of “reduced brain reserve.” Other possible long-term
consequences of TBI are the development of aging-related
Parkinson’s disease, which co-occurs commonly with AD,
amyotrophic lateral sclerosis [40], and other neurodegenera-
tive disorders that involve coincidental cerebrovascular dis-
ease pathology [41]. A systematic review of the literature
supported an association between a history of head injury
inmales and future development of AD (summary odds ratio,
2.29; range, 1.47–3.58) [1]. PTSD is an anxiety disorder that
develops in some individuals after exposure to traumatic
stress [42]. PTSD symptoms include flashbacks or night-
mares and avoidance of stimuli; and increased anger, arousal,
and hypervigilance [43–45]. Although these symptoms
abate, they can persist for years or even decades [44]. The
overall lifetime prevalence of PTSD in U.S. combat veterans
is estimated at 6% to 31% [46,47]. The neuropathology
underlying PTSD, separate from that associated with TBI,
is completely unknown [40].
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AD and dementia in veterans [2]. However mechanisms of
brain volume loss, cognitive impairment, and increased
risk for dementia in PTSD are not known and may include
reduced “cognitive reserve” suggested by impaired verbal
memory in PTSD [48,49]; brain alterations in the
hippocampus [50–54], anterior cingulate [52], and prefrontal
structures (reviewed in [55]); or the association of PTSDwith
independent risk factors for dementia such as smoking, hy-
pertension, hyperlipidemia, diabetes, obesity, inflammation,
and major depression [56–58]. No study has examined
whether PTSD is associated with increased deposition of
AD-like tau or Ab pathologies, Parkinson’s disease-like
Lewy bodies formed by a synuclein amyloid fibrils, or
TDP-43 inclusions that are signatures of frontotemporal
lobar degeneration and amyotrophic lateral sclerosis.2. Aims and scope of the study
This study aims to investigate the associations between a
history of TBI and/or current PTSD and brain AD pathology
using methodology, infrastructure, and data collection tech-
niques currently in use in the Alzheimer’s Disease Neuroi-
maging Initiative (ADNI). ADNI [59–61] is a large
public–private partnership that aims primarily to validate
imaging and biomarkers for AD clinical trials.
Standardized longitudinal, clinical, and cognitive [62,63]
MRI [64]; fluorodeoxyglucose–PET and Pittsburgh com-
pound B–PET [65]; blood and CSF biomarkers [66]; and ge-
netics measurements [67,68] have been made on more than
800 participants. In 2010, funded by the federal stimulus
package, the ADNI study moved into the “ADNI GO”
phase. The ADNI GO research effort is the first of its kind
to focus on participants who exhibit the earliest signs of
memory loss in mild cognitive impairment (MCI)—both
thought to be precursors to AD. The ADNI2 phase of the
study commenced in 2011 and is modeled after the original
ADNI study. ADNI2 uses clinical/cognitive tests, lumbar
puncture for the collection of CSF, 3-T MRI, florbetapir am-
yloid PET scans, and fluorodeoxyglucose PET scans [69–72],
and has enrolled a large cohort of new healthy control
volunteers and subjects with early MCI, late MCI, and AD;
and a new group consisting of those with subjective
memory complaints. Across these three phases, more than
1600 unique participants have been enrolled. Subjects are
seen at 59 sites throughout the United States and Canada.
For this study,we are enrolling three additional groups from
military and veterans’ records: (1) veteranswith past history of
TBI with or without PTSD, (2) veterans with ongoing PTSD
without TBI, and (3) veteran control subjects comparable in
age, gender, education, socioeconomic status to groups 1
and 2 who have no MCI or dementia. An attempt will also
be made to match ethnicity. To maximize the statistical power
to detect the effects of a history of TBI or ongoing PTSD on
cognition, subjects with MCI will be excluded, because evi-
dence of AD pathology has been reported in 50% to 60% ofthese subjects [73–75], and this would increase the difficulty
in detecting an effect of PTSD or TBI. Furthermore, several
groups (Drs. C. Rowe and M. Mintun, pers. comm.) have
found that the effects of the APOE ε4 allele and age on
amyloid PET positivity are more significant in cognitively
normal subjects compared with patients with MCI or AD.
Therefore, we will study subjects with normal cognition who
are expected to have an age-associated prevalence of brain
AD pathology of 10% to 30% [76–78].
3. Study hypotheses and exploratory analyses
Using the three groups, we are testing the primary hypoth-
esis that veterans with a history of moderate to severe TBI
and/or PTSD have increased evidence forAD pathophysiolog-
icalmarkers (greater uptake on florbetapir amyloid PET scans,
lower CSFAb levels, greater CSF tau and phosphorylated tau
(p-tau) levels, greater baseline and longitudinal medial tempo-
ral brain atrophy, reduced baseline cognitive function, and a
greater rate of change of cognitive function, particularly in de-
layed recall) compared with control subjects. Other major hy-
potheses are (1) that TBI and/or PTSD reduce cognitive
reserve, causing greater cognitive impairment after accounting
for age, educational status, prewar cognitive function, brain
amyloid load, or hippocampal volume; and (2) that there are
significant correlations between severity of TBI and/or the
severity of PTSD, and greater cognitive impairment. We are
also seeking to replicate reports that TBI is associated with
reduced microstructural integrity in brain white matter in spe-
cific brain regions [79–81] and that PTSD is associated with
reduced hippocampal volume compared with control
subjects [50–54].
In addition, we are investigating whether TBI and PTSD
alter the patterns of amyloid distribution or brain atrophy
among TBI, PTSD, and control subjects, and whether these
differ from patterns of nonveteran subjects in ADNI. We are
also studying the relationship between cortical areas with am-
yloid deposition and underlying white matter integrity to
determine whether axonal injury resulting from TBI is associ-
ated with greater amyloid accumulation or with less amyloid
accumulation resulting from disconnection and reduced brain
activity. We expect that these exploratory analyses will have
low statistical significance after correction for multiple com-
parisons, and that they will require future replication.
4. Methods
This entire study has been approved by the Committee on
Human Research at the University of California at San Fran-
cisco, the San Francisco VA Medical Center Research and
Development Committee, and the Department of Defense
Human Research Protection Office. All patients provide
informed consent before being enrolled in the study.
4.1. Research participant selection and exclusion criteria
Vietnam veterans aged 60 to 80 years with documented
history of TBI with or without PTSD, with ongoing PTSD
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age, gender, and education are being identified from Veter-
ans Affairs records. Inclusion criteria for subjects with
TBI are a documented history of moderate–severe nonpene-
trating TBI that may be related to military service during the
VietnamWar or to another trauma, and either no evidence or
some evidence of PTSD (Clinician Administered PTSD
Scale [CAPS] [82] score, .30 points). A minimum CAPS
score of 40 points and no history of head trauma are required
for inclusion in the PTSD group. Control subjects have no
documented or self-history report of TBI, and no CAPS
score greater than 29 points. Individuals are excluded from
the study for potentially confounding factors, including a
history of psychotic or neurologic illnesses, a recent history
of alcohol or substance abuse, the presence of metal implants
or claustrophobia that would prevent subjects undergoing
MRI testing, and contraindications for lumbar puncture
PET scan, or other procedures in this study.
4.2. Telephone screening and self-report assessments
Veteran volunteers within 150 miles of approved Depart-
ment of Defense (DOD) ADNI sites are contacted initially
by letter or by phone. Consenting volunteers undergo a tele-
phone prescreen interview to document any history of TBI,
including military-associated injury and all other traumas.
Volunteers are questioned about their use of drugs and
alcohol, medical history, current use of medications, and
memory. The purpose of the prescreen interview is to rule
out volunteers with exclusionary criteria, such as possible
MCI or dementia (based on theTelephone InterviewCognitive
Status assessment), inability to undergo MRI as a result of
claustrophobia, or the presence of metal in the body, and other
health issues that wouldmake it unsafe for them to participate.
Volunteers who pass the prescreen interview and who have
given documented consent are then assessed using CAPS
[82], which identifies PTSD and other exclusionary factors,
such as psychotic illnesses (using theStructuredClinical Inter-
view for theDiagnostic and Statistical Manual ofMental Dis-
orders, fourth edition, nonpatient edition [83]; the Life
Stressor Checklist, Revised; and the Addiction Severity Index
Lite [84,85]). The following self-reportmeasures aremailed to
subjects and collected at the time of neurocognitive testing at
the DOD ADNI sites: the Symptom Check-List-90-Revised
[86], the Pittsburgh Sleep Quality Index [87], smoking status
[88], number of pack years [89], the Short Form-12 Health
Survey [90], and the Combat Exposure Scale [91].
After the Clinical telephone interview, eligible volunteers
are referred to DODADNI sites for neurocognitive and clin-
ical testing and imaging studies at baseline and at a 1-year
follow-up.
4.3. Neurocognitive testing
At DOD ADNI sites, all participants are given the ADNI
battery of neuropsychological tests designed to take fullest
advantage of the APOE genotype, amyloid, and AD trajec-tories of decline for study data interpretation, in addition
to the Armed Forces Qualification Test, which is unique to
the DOD ADNI study [92,93]. The battery consists of the
Montreal Cognitive Assessment [94], everyday cognition
[95], the Mini-Mental State Examination, the Alzheimer’s
Disease Assessment Scale–Cognitive 13 [96], the Logical
Memory Test I and II (Delayed Paragraph Recall) [97], the
Boston Naming Test [98], the Category Fluency Test [99],
theClockDrawingTest, theAmericanNationalAdultReading
Test [100], the Auditory Verbal Learning Test [101], the Trail
Making Test Parts A and B [102–104], the Clinical Dementia
Rating [105], the Activities of Daily Living/Functional
Assessment Questionnaire [106], the Neuropsychiatric Inven-
tory [107], and the Geriatric Depression Scale [108]. Informa-
tion is also obtained on education level, a proxy for
socioeconomic status [109], and health and cognitive status,
including the Armed Forces Qualification Test taken during
basic training (if available) to determinewhether cognitive sta-
tus before combat is predictive of AD or PTSD.
4.4. Classification of subjects using CSF biomarkers
CSF is obtained at baseline using lumbar puncture and is
analyzed with established ADNI methods [63]. Briefly, CSF
samples will be assayed to measure levels of Ab42, total tau
(t-tau) and tau phosphorylated at threonine 181 (p-tau181) us-
ing the validated Luminex xMAP multiplex immunoassay
platform [4,110–112]. The established pathological AD
“signature” of biomarkers consisting of predefined cutoff
values of t-tau, p-tau181, and Ab42 levels that are
predictive of AD [110,112] is being used in combination
with the logistic regression of tau, Ab, and APOE ε4
alleles model [111] to delineate subjects with probable AD.
4.5. Imaging studies4.5.1. Florbetapir amyloid imaging
Amyloid PET images are acquired using the radiotracer
florbetapir ([18F]AV-45) [70–73], with a Hoffman phantom
reference, at participating PET centers. Acquisition and
analysis is identical to previously published methods used
in ADNI [113].
4.5.2. Magnetic resonance imaging
Imaging is performed on qualified ADNI GE systems
[113]. Briefly, the protocol consists of the following image
sequences: (1) a three-dimensional, T1-weighted volumetric
scan using the inversion recovery - spoiled gradient recalled
echo sequence (GE product analog to MPRAGE) [113]; (2)
fluid attenuated inversion recovery to detect quantitative
measures of white matter hyperintensity burden, and for
qualitative grading of lacunar infarctions and evidence of
closed head injury; (3) T2* gradient echo to capture evi-
dence of hemosiderin deposition, which could indicate
remote cortical contusion, shearing injury, or prior subarach-
noid hemorrhage; (4) diffusion tensor imaging, as previously
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shearing injury; and (5) resting-state task-free functional
MRI consisting of 103 volumes at 3.3-mm3 resolution with
a duration of 7 minutes to investigate the role of the func-
tional network in dementia. Three-dimensional T1-
weighted volumetric images are analyzed using FreeSurfer
software (Athinoula A. Martinos Center for Biomedical Im-
aging, Boston, MA, USA) [114], and volume measurements
of anatomic brain regions and geometric measures of
cortical regions will be computed. Images will be analyzed
using identical methods to ADNI.
4.6. Statistical analysis
Primary hypotheses will be tested statistically using uptake
on florbetapir scans; CSF Ab; t-tau and p-tau181; volumes of
the hippocampus, entorhinal cortex, and parietal/temporal
cortices; diffusion tensor imaging summary measures; and
measures of cognitive function as primary outcomes. Baseline
levels and change (difference scores between month 12 and
baseline assessments) will be compared among groups using
analysis of variance. When the global F-test for group differ-
ence is significant, post hoc pairwise tests, adjusting for mul-
tiple comparisons using the Bonferroni or Tukey’s Honestly
Significant Difference approach, will be used to identify spe-
cific group differences. Linear regression models will be used
to account for potential confounders, including the presence of
an APOE ε4 allele. A priori power analyses for each class of
primary hypotheses have been calculated using nQuery
[115] assuming a two-sided test.
4.7. Informatics and data release
All data are deidentified and uploaded to the Alzheimer’s
Disease Cooperative Study database at the University of Cal-
ifornia San Diego, and all magnetic resonance images and
PET scans are uploaded to the Laboratory of Neuroimaging
database [116] to be available, like ADNI data, to all quali-
fied scientists, without embargo.Table 1
Summary of each phase of the recruitment effort
Mail effort Call effort
Completed
screens
Consents
sent
8113 4372 1356 60
Brochures mailed Subjects called Subjects
screened
Waiting 14.9%
1005 765 990 90
12.4% 17.5% 73.0% 24.6%
Respond yes Subjects decline Subjects
excluded
Subjects declined
367 1356 366 214
4.5% 31.0% 27.0% 58.5%
Respond no Subjects screened Consents
mailed
Signed and receive
Abbreviations: SCID, Structured clinical interview for the Diagnostic and S
Administered PTSD Scale; TBI, traumatic brain injury; PTSD, posttraumatic stre5. Current study progress
The names and contact information of Vietnam veterans
who are service connected for PTSD and/or TBI were iden-
tified from Veterans Affairs compensation and pension re-
cords and Veterans Affairs health records. An additional
group of Vietnam veterans service connected for traumas
not related to PTSD, head trauma, or dementia were selected
for the control group.
All subjects are contacted initially by mail, with a tele-
phone follow-up to complete a prescreen interview to assess
eligibility for study enrollment. The mail effort includes a
letter, brochure, and response postcard. Subjects can call
the toll-free study number or return the postcard and partic-
ipate in the prescreen interview or opt out. Study staff call
veterans who express interest and those who have not re-
sponded. No calls are made to those who have opted out.
Table 1 summarizes the current prescreen effort. To date,
8113 letters have been mailed to selected Vietnam veterans.
The overall response to this initial mail effort has been pos-
itive, as 12.4% of subjects expressed a desire to participate,
whereas 4.5% declined. Telephone calls have been made to
4372 subjects. Of those called, 765 have declined (17.5%).
The main reasons for declining are “not interested” and/or
“too much involved” (lumbar puncture, PET, MRI). About
a third (31.0%) completed the prescreen interview. The
exclusion rate of those that completed this screen is
73.0%. The main reasons for excluding a subject involve cir-
cumstances that make it unsafe for the subject to undergo an
MRI, a PET scan, or a lumbar puncture, such as metal or
shrapnel in the body, unstable medical conditions, or current
use of certain medications. Those subjects who complete the
screening questions and are found to be eligible are mailed a
consent form. Currently, 366 subjects (27.0%) have been
sent a consent form and additional health and medical ques-
tionnaires. Again, the response to the study has been posi-
tive; only 24.6% of subjects who received the consent
form declined to participate, whereas 214 (58.5%) signedSigned consents
received
SCID CAPS
referrals
Clinic referrals
by cohort
214 3 TBI only, 19 (20%);
both, 15 (15.8%)
Signed and received Scheduled TBI/both, 35.8%
55 61 46
25.7% 39.1% 48.4%
Subjects excluded Subjects failed PTSD only
159 95 15
74.3% 60.9% 15.8%
d Referred SCID CAPS Passed to clinic Control subjects
tatistical Manual of Mental Disorders, fourth edition; CAPS, Clinician-
ss disorder.
Respond yes Respond no
SCID/CAPS
 TBI and PTSD Control subjects
Fig. 1. Summary of each phase of the recruitment effort. SCID, Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders,
fourth edition; CAPS, Clinician-Administered PTSD Scale; TBI, traumatic brain injury; PTSD, posttraumatic stress disorder.
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office, the additional health forms are reviewed by staff to
ensure subject safety. An additional 25.7% have been
excluded at this stage as a result of the disclosure of other
health issues not reported in the prescreen. Subjects who
have given written consent to the study and who are assessed
as safe to continue are next referred for a structured clinical
interview (Structured clinical interview for the Diagnostic
and Statistical Manual of Mental Disorders, fourth edition
CAPS); to date, 159 subjects (74.3%) of those who returnedtheir signed forms have been referred to the clinical inter-
view, which assesses the presence of PTSD, other psycho-
logical disorders, and drug and alcohol abuse. Currently,
39.1% of subjects were excluded after the clinical interview
because they did not have current PTSD (for the PTSD
cohort) or they disclosed an exclusionary criterion (e.g.
drug and/or alcohol abuse, schizophrenia, bipolar disorder).
Subjects who match one of the study cohorts and do not meet
any exclusionary criteria are referred to the clinic for addi-
tional screening procedures (medical history, cognitive
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referred to the clinical interview have also been referred to
one of the study clinics: 46 (48.4%) of the total clinic refer-
rals are in the PTSD-only cohort, 19 subjects (20.0%) are in
the TBI-only cohort, 15 (15.8%) are in the combined cohort
(TBI and some PTSD), and 15 (15.8%) are control subjects.
Subjects who meet all inclusion criteria after completing the
screening procedures at the clinic are formally enrolled in
the study. As of November 4, 2013, 19 of 95 subjects referred
to the clinics have completed the screening battery and have
been enrolled. The screening and enrollment process and
progress to date are summarized in Table 1 and Fig. 1.6. Limitations of the study
One potential limitation of this study design is that TBI
and PTSD may be associated with a much greater incidence
of MCI and dementia, and by excluding such subjects from
our study we may be biasing the sample. This limitation is
now offset by the funding of an additional study of similar
magnitude that is focusing on subjects with MCI. Another
limitation is that it will not be possible to distinguish cogni-
tive impairment and MCI resulting from AD pathology from
cognitive impairment and MCI resulting from TBI or other
factors by telephone interview.7. Conclusions
In conclusion, this study is designed to provide sufficient
power to detect the main effects of TBI and PTSD on AD pa-
thology measured with imaging and biomarkers. The results
of these studies may provide insight into the question of
whether TBI and PTSD alter the pattern of cognitive impair-
ments, amyloid distribution, or brain atrophy. The results of
this study may provide insight into the question of whether
or not TBI and PTSD alter the pattern of cognitive impair-
ments, amyloid distribution or brain atrophy and may even-
tually lead to an AD prevention trial in veterans with risk
factors for the development of AD.Acknowledgments
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